[HTML][HTML] PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance
The Poly (ADP-ribose) polymerase (PARP) family has many essential functions in cellular
processes, including the regulation of transcription, apoptosis and the DNA damage …
processes, including the regulation of transcription, apoptosis and the DNA damage …
PARP and PARG inhibitors in cancer treatment
D Slade - Genes & development, 2020 - genesdev.cshlp.org
Oxidative and replication stress underlie genomic instability of cancer cells. Amplifying
genomic instability through radiotherapy and chemotherapy has been a powerful but …
genomic instability through radiotherapy and chemotherapy has been a powerful but …
Molecular mechanisms of chemo‐and radiotherapy resistance and the potential implications for cancer treatment
YP Liu, CC Zheng, YN Huang, ML He, WW Xu… - MedComm, 2021 - Wiley Online Library
Cancer is a leading cause of death worldwide. Surgery is the primary treatment approach for
cancer, but the survival rate is very low due to the rapid progression of the disease and …
cancer, but the survival rate is very low due to the rapid progression of the disease and …
PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers
A mounting body of evidence now indicates that PARP inhibitors have the potential to be
used as a foundation for both monotherapy and combination strategies across a wide …
used as a foundation for both monotherapy and combination strategies across a wide …
Combination olaparib and temozolomide in relapsed small-cell lung cancer
AF Farago, BY Yeap, M Stanzione, YP Hung, RS Heist… - Cancer discovery, 2019 - AACR
Small-cell lung cancer (SCLC) is an aggressive malignancy in which inhibitors of PARP
have modest single-agent activity. We performed a phase I/II trial of combination olaparib …
have modest single-agent activity. We performed a phase I/II trial of combination olaparib …
[HTML][HTML] New approaches to SCLC therapy: from the laboratory to the clinic
JT Poirier, J George, TK Owonikoko, A Berns… - Journal of Thoracic …, 2020 - Elsevier
The outcomes of patients with SCLC have not yet been substantially impacted by the
revolution in precision oncology, primarily owing to a paucity of genetic alterations in …
revolution in precision oncology, primarily owing to a paucity of genetic alterations in …
Application of animal models in cancer research: recent progress and future prospects
Z Li, W Zheng, H Wang, Y Cheng, Y Fang… - Cancer management …, 2021 - Taylor & Francis
Animal models refers to the animal experimental objects and related materials that can
simulate human body established in medical research. As the second-largest disease in …
simulate human body established in medical research. As the second-largest disease in …
PARP inhibitors in cancer diagnosis and therapy
Targeting of PARP enzymes has emerged as an effective therapeutic strategy to selectively
target cancer cells with deficiencies in homologous recombination signaling. Currently used …
target cancer cells with deficiencies in homologous recombination signaling. Currently used …
Recent developments in the treatment of small cell lung cancer
BI Hiddinga, J Raskin, A Janssens… - European …, 2021 - Eur Respiratory Soc
Small cell lung cancer (SCLC) comprises about 15% of all lung cancers. It is an aggressive
disease, with early metastasis and a poor prognosis. Until recently, SCLC treatment …
disease, with early metastasis and a poor prognosis. Until recently, SCLC treatment …
PARP inhibitor plus radiotherapy reshapes an inflamed tumor microenvironment that sensitizes small cell lung cancer to the anti-PD-1 immunotherapy
N Zhang, Y Gao, Z Huang, P Dai, Y Luo, Q Wu, X Jiang… - Cancer Letters, 2022 - Elsevier
Small cell lung cancer (SCLC) is a highly malignant tumor with extremely poor prognosis.
The treatment strategy is very limited, and patient outcomes remain dismal with the 5-year …
The treatment strategy is very limited, and patient outcomes remain dismal with the 5-year …